T1	p 124 141	type 1 diabetes .
T2	p 242 274	diagnosis with type 1 diabetes (
T3	p 344 367	diagnosis with standard
T4	p 513 525	subcutaneous
T5	p 562 619	24 patients , 8-18 years old , with newly diagnosed T1D .
T6	p 634 643	evaluated
T7	p 706 718	diagnosis of
T8	p 1394 1415	pump-treated subjects
T9	p 1494 1511	subjects reported
T10	i 6 26	Insulin pump therapy
T11	i 320 340	insulin pump therapy
T12	i 368 390	multiple daily insulin
T13	i 485 496	MDI therapy
T14	i 502 558	continuous subcutaneous insulin therapy ( pump therapy )
T15	i 932 957	continuous glucose sensor
T16	i 1118 1130	pump therapy
T17	i 1614 1634	insulin pump therapy
T18	i 1808 1820	pump therapy
T19	o 73 89	glycemic control
T20	o 105 120	?-cell function
T21	o 172 218	preserving residual insulin secretory capacity
T22	o 391 401	injections
T23	o 741 758	insulin secretion
T24	o 770 816	by mixed-meal-stimulated C-peptide secretion ,
T25	o 896 921	glycosylated hemoglobin (
T26	o 958 1037	data , insulin utilization , anthropometric measures , and patient satisfaction
T27	o 1191 1244	mixed-meal tolerance test-stimulated C-peptide values
T28	o 1353 1369	glycemic control
T29	o 1423 1472	time spent with normoglycemia , better mean HbA1c
T30	o 1657 1673	glycemic control
T31	o 1680 1696	well tolerated ,
T32	o 1725 1745	patient satisfaction
T33	o 1844 1868	residual ?-cell function